Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Supernus Pharmaceuticals, Inc. (SUPN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Supernus is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases, and its filings offer detailed insight into its commercial portfolio, collaborations, and pipeline.
Supernus’s current reports on Form 8-K cover a range of material events. These include announcements of quarterly financial results, where the company reports total revenues, net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products, as well as royalty, licensing and other revenues and collaboration revenue from ZURZUVAE. Filings also describe non-GAAP measures like adjusted operating earnings and revenues excluding certain legacy products.
Other 8-K filings document corporate transactions, notably the acquisition of Sage Therapeutics, Inc. Supernus details the merger structure, consideration, contingent value rights (CVRs) tied to ZURZUVAE milestones, and the integration of Sage as a wholly owned subsidiary. These filings also outline the collaboration economics with Biogen Inc. related to ZURZUVAE, an oral treatment for postpartum depression.
Additional disclosures address operational updates, such as supply constraints for ONAPGO due to stronger than expected demand and the company’s decision to prioritize existing patients while working to rebuild inventory. Filings also announce upcoming earnings release dates and conference calls, reinforcing the company’s regular reporting cadence.
On Stock Titan, investors can use AI-powered tools to read concise summaries of Supernus’s 8-Ks and other SEC documents, quickly understand key points about CNS product performance, collaboration revenue, acquisitions, and pipeline developments, and identify items such as contingent value rights or other material agreements without manually parsing lengthy filings.
Supernus Pharmaceuticals President and CEO Jack A. Khattar reported the acquisition of 38,640 Performance Share Units at a price of $0.00 per unit. These units were awarded on February 22, 2024, with a portion vesting upon achievement of individual performance objectives set on June 24, 2024.
SUPERNUS PHARMACEUTICALS, INC. reported that Senior Vice-President & CFO Timothy C. Dec acquired performance share units. On the reported transaction date, 3,000 performance share units were credited to his direct holdings at no exercise price. According to a footnote, these units were originally awarded on February 22, 2024, with a portion vesting upon achievement of individual performance objectives established on June 24, 2024.
SUPERNUS PHARMACEUTICALS, INC. reported an insider equity award for senior vice president and Chief Technology Operations Officer Frank Mottola. He acquired 3,750 Performance Share Units at a stated price of $0.00 per unit, leaving him with 3,750 such derivative securities held directly after the transaction.
According to the footnote, these Performance Share Units were originally awarded on February 23, 2023, with individual performance objectives for a defined performance period established on June 12, 2023. A portion of that award vested upon achievement of these objectives, and the reported acquisition reflects this vesting-based grant.
Supernus Pharmaceuticals files its annual report describing a CNS-focused business built around branded neurology and psychiatry drugs plus a deep pipeline. The company markets Qelbree for ADHD, multiple Parkinson’s disease therapies (GOCOVRI, APOKYN, ONAPGO, XADAGO), epilepsy and migraine drugs Trokendi XR and Oxtellar XR, MYOBLOC for cervical dystonia and sialorrhea, and ZURZUVAE for postpartum depression.
A major 2025 milestone was acquiring Sage Therapeutics for $8.50 per share in cash (about $561 million) plus contingent value rights worth up to $3.50 per share (about $234 million) tied mainly to ZURZUVAE sales and Japanese approval milestones. Supernus shares ZURZUVAE economics in the U.S. with Biogen and licenses zuranolone rights in parts of Asia to Shionogi.
The company highlights late-stage R&D assets including SPN‑817 for epilepsy, SPN‑820 targeting treatment‑resistant depression via mTORC1 modulation, and SPN‑443, a triple reuptake inhibitor being developed for ADHD. Manufacturing is fully outsourced to global CMOs, and three large wholesalers together account for more than 76% of 2025 product revenue.
SUPERNUS PHARMACEUTICALS, INC. senior vice president Frank Mottola reported routine equity compensation activity. On February 25, 2026, 1,875 restricted stock units were disposed of to the issuer and simultaneously settled into 1,875 shares of common stock as part of a vesting event.
In a separate transaction the same day, 977 shares of common stock were disposed of through a tax-withholding disposition at $50.69 per share to satisfy withholding obligations tied to the RSU vesting. After these transactions, Mottola directly owned 18,106 shares of common stock.
Supernus Pharmaceuticals Senior Vice-President & CFO Timothy C. Dec reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 25, 2,500 RSUs were settled into 2,500 shares of common stock, and 1,279 of those shares were withheld by the company to cover tax obligations at a price of $50.69 per share. After these transactions, Dec directly owned 5,115 shares of common stock. Each RSU represents one share of common stock and vests in four equal annual installments beginning on February 23, 2024.
SUPERNUS PHARMACEUTICALS, INC. Sr. VP of IP and CSO Padmanabh P. Bhatt reported equity award-related transactions. A grant of 1,250 shares of common stock was acquired at a price of $0.00, tied to restricted stock units that convert into one share each upon vesting.
On the same date, 1,250 restricted stock units were disposed back to the issuer and 650 shares of common stock at $50.69 were withheld by the company to cover tax obligations in connection with RSU vesting, rather than sold on the open market.
Supernus Pharmaceuticals executive Jonathan Rubin, SVP and Chief Medical Officer, reported equity award activity and related share transactions. He disposed of 1,250 restricted stock units back to the issuer and simultaneously acquired 1,250 shares of common stock at $0.00 per share as a grant. To cover taxes on the RSU vesting, 675 shares of common stock were automatically disposed of at $50.69 per share, with the company withholding these shares to satisfy tax obligations. Following these transactions, Rubin directly owned 13,341 shares of Supernus common stock.
SUPERNUS PHARMACEUTICALS, INC. Senior Vice-President & CFO Timothy C. Dec reported multiple equity compensation transactions on February 24, 2026. Restricted stock units were disposed back to the issuer as they vested, and related common stock was acquired. Some common shares were then delivered to cover tax withholding obligations at prices around $51 per share. Footnotes explain that each restricted stock unit converts into one common share and that various RSU grants vest in four equal annual installments beginning on February 19, 2026, February 22, 2023, and February 22, 2025.